Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 25NETWORK 17NIH 16INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Gastrointestinal 1

Conditions

Pathologic Complete Response 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Observation × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01039376 2019-07-30

PROLONG

Novartis

Phase 3 Terminated
480 enrolled 30 charts
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00759109 2017-04-07

Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)

Merck Sharp & Dohme LLC

Phase 3 Completed
150 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡